RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
  Genetic Disorders
  X Chromosome
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Genetics Channel

subscribe to Genetics newsletter
Latest Research : Genetics

   EMAIL   |   PRINT
Japanese haplotypes would help in identifying genes associated with disease and drug response

Oct 29, 2005 - 4:29:00 PM
“Understanding the patterns of genetic variation in the Japanese population will greatly enhance our ability to identify genes associated with disease and drug response."

[RxPG] Researchers at Kyushu University of Japan, in collaboration with Perlegen Sciences, Inc., have identified common patterns of human DNA sequence variation, or haplotypes, in the Japanese population. By combining a unique set of DNA samples collected at the Medical Institute of Bioregulation at Kyushu University with Perlegen’s high throughput, whole-genome analysis approach, based on next generation Affymetrix GeneChip ® technology, the collaborators identified common haplotypes that can be used to conduct comprehensive genetic research on human disease and variable response to medicines.

“Understanding the patterns of genetic variation in the Japanese population will greatly enhance our ability to identify genes associated with disease and drug response” stated Dr. Kenshi Hayashi, Professor of the Research Center for Genetic Information, Medical Institute of Bioregulation at Kyushu University. “The unique approach of this study complements the recently completed International HapMap project. Both studies make critical contributions to enabling personalized medicine in Japan.”

The collaboration between Kyushu University and Perlegen Sciences was particularly effective in identifying long-range haplotypes (over one million bases long). “With this study, Dr. Hayashi and his colleagues at Kyushu University have made an important contribution to medical research in Japan,” stated David Cox, Chief Scientific Officer of Perlegen. “It will enable researchers to identify the genetic factors that determine why drugs work well for some patients, but not for others.”

"Collaborating with the top researchers in Japan such as Dr. Hayashi is a priority for Perlegen,” stated Akira Usui, General Manager of Perlegen Japan, KK. “We are committed to improving the therapeutic treatments available to Japanese patients.”

Kyushu University and Perlegen Sciences will report their findings in the October 26 issue of Genome Research.

Publication: Kyushu University
On the web: www.perlegen.com 

Advertise in this space for $10 per month. Contact us today.

Related Genetics News
Genetic study of bedbugs may help identify pesticide resistance genes
Novel method of database analysis to help identify responsible genes and diagnostic markers
Environmental influences can be passed down to the next generation
Gene found to be key in etiology of cleft palate
History, geography also seem to shape our genome
Induced pluripotent stem cell lines from pigs
Egg cells help extend life of sperms
Family of genes known as KRAB-ZFP regulate genes dealing with stress
New screening strategy increases Down's syndrome detection before birth
Can genetic research spur racist attitudes?

Subscribe to Genetics Newsletter

Enter your email address:

 Additional information about the news article
About Kyushu University

Founded in 1903 as the Fukuoka Medical College, Kyushu University is one of the leading universities in Japan, with over 16,000 students, over 2,000 faculty and over 6,000 researchers in a variety of schools, institutes and hospitals. The Research Center for Genetic Information, founded in 1993, is part of Kyushu University’s Medical Institute of Bioregulation. The center focuses on developing DNA analytical technologies and investigating genetic factors for hereditary diseases.


Dr. Kenshi Hayashi

Director, Division of Genome Analysis

Research Center for Genetic Information

Medical Institute of Bioregulation

Kyushu University

[email protected]

About Perlegen Sciences

Perlegen Sciences, Inc. and Perlegen Sciences Japan, K.K. are working to provide safe and effective medicines to the world. The companies quickly and cost effectively analyzes millions of genetic variations in DNA samples obtained from clinical trial participants. This information is used to explain and predict the efficacy and adverse effect profiles of prescription drugs. Perlegen also applies this expertise to discovering genetic variants associated with disease for potential new therapeutics and diagnostics. For years, scientists and drug manufacturers have been eager to comprehensively examine entire genomes; through Perlegen, this is now possible. Perlegen is able to bring drugs to the market that may otherwise have been discontinued in clinical development.

Based in Mountain View, California, Perlegen Sciences was formed in late 2000 as a spin-off from Affymetrix, Inc. (Nasdaq: AFFX). For more information about the company and its technologies, visit Perlegen's website at www.perlegen.com. Perlegen Sciences, Perlegen, and the Perlegen logo are trademarks of Perlegen Sciences, Inc.


Perlegen Sciences, Inc.
Paul Cusenza
Senior Vice President
(650) 625-4500

Perlegen Sciences Japan, KK

Akira Usui

Representative Director & General Manager

+81 (0)3 3444-6080
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)